Investment in Prolysis Ltd

Oxford Technology 2 VCT PLC
20 June 2001


Oxford Technology 2 VCT has invested £150,000 in Prolysis Ltd as part of a
larger round that raised a total of £700,000 for the company.

Prolysis Ltd was established in 1998 as an antibiotic discovery company to
exploit high throughput screening technology developed by Professor Jeffrey
Errington of the Dunn School of Pathology, University of Oxford. The patented
screening technology enables chemical libraries to be rapidly checked for new
compounds with specific activity against a series of novel bacterial targets.
The sensitivity of the screen allows suboptimal compounds to be identified
which can then be optimised using combinatorial chemistry.


The purpose of the investment is to provide the company with working capital
to enable it to achieve significant milestones over the next twelve months.


For further information, please contact Oxford Technology 2 VCT on 01865
784466.